Diane Descamps

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study (2009)

Landman, Roland, Capitant, Catherine, Descamps, Diane, Chazallon, Corine, Peytavin, Gilles, Katlama, Christine, ...

Objectives We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label...

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients (2009)

Descamps, Diane, Lambert-Niclot, Sidonie, Marcelin, Anne-Geneviève, Peytavin, Gilles, Roquebert, Bénédicte, Katlama, Christine, ...

Objective The aim of the study was to identify a pattern of protease gene mutations associated with the virological response to darunavir/ritonavir-based regimens. Patients and methods We analysed...

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. (2008)

Desbois, Delphine, Roquebert, Bénédicte, Peytavin, Gilles, Damond, Florence, Collin, Gilles, Bénard, Antoine, ...

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir....

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. (2008)

Desbois, Delphine, Roquebert, Bénédicte, Peytavin, Gilles, Damond, Florence, Collin, Gilles, Bénard, Antoine, ...

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir....

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. (2008)

Desbois, Delphine, Roquebert, Bénédicte, Peytavin, Gilles, Damond, Florence, Collin, Gilles, Bénard, Antoine, ...

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir....

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide (2008)

Descamps, Diane, Assoumou, Lambert, Masquelier, Bernard, Marcelin, Anne-Geneviève, Saidi, Souhila, Tamalet, Catherine, ...

Objectives We studied gp41 mutations associated with failing enfuvirtide salvage therapy. Methods This multicentre study involved patients with HIV-1 plasma viral load (pVL) > 5000 copies/mL after...

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. (2008)

Desbois, Delphine, Roquebert, Bénédicte, Peytavin, Gilles, Damond, Florence, Collin, Gilles, Bénard, Antoine, ...

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir....

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. (2008)

Desbois, Delphine, Roquebert, Bénédicte, Peytavin, Gilles, Damond, Florence, Collin, Gilles, Bénard, Antoine, ...

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir....

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors. (2008)

Desbois, Delphine, Roquebert, Bénédicte, Peytavin, Gilles, Damond, Florence, Collin, Gilles, Bénard, Antoine, ...

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir....

HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms (2003)

Ravela, Jaideep ; JFA; CORA, Betts, Bradley J, Brun-Vézinet, Francoise, Vandamme, Anne-Mieke; U0004051 ;, Descamps, Diane, Van Laethem, Kristel; U0035492 ;, ...

Several rules-based algorithms have been developed to interpret results of HIV-1 genotypic resistance tests. To assess the concordance of these algorithms and to identify sequences causing...

Quantification of Proviral Load of Human Immunodeficiency Virus Type 2 Subtypes A and B Using Real-Time PCR

Damond, Florence, Descamps, Diane, Farfara, Isabelle, Telles, Jean Noël, Puyeo, Sophie, Campa, Pauline, ...

We have developed and evaluated a new method to quantify human immunodeficiency virus type 2 (HIV-2) proviral DNA based on LightCycler real-time PCR. The assay has a detection limit of 5 copies/105...

Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors

Masquelier, Bernard, Race, Esther, Tamalet, Catherine, Descamps, Diane, Izopet, Jacques, Buffet-Janvresse, Claudine, ...

Genomic rearrangements in the 5′ part of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) have been involved in multidrug resistance to nucleoside RT inhibitors (NRTI). We...

Highly Sensitive Method for Amplification of Human Immunodeficiency Virus Type 2 DNA

Damond, Florence, Loussert-Ajaka, Ibtissam, Apetrei, Cristian, Descamps, Diane, Souquière, Sandrine, Leprêtre, Annie, ...

We evaluated a new human immunodeficiency virus type 2 (HIV-2) DNA amplification strategy based on peripheral blood mononuclear cell long PCR (XL PCR) followed by nested PCR amplification. The...

Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis

Descamps, Diane, Calvez, Vincent, Collin, Gilles, Cécille, Agnès, Apetrei, Cristian, Damond, Florence, ...

We compared the line probe assay (LiPA) to sequence analysis for the detection of mutations conferring resistance to nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse...

Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants

Yerly, Sabine, Rakik, Abdelrahim, Kinloch De Loes, Sabine, Hirschel, Bernard, Descamps, Diane, Brun-Vézinet, Françoise, ...

Sequences of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) domain were determined by direct sequencing of HIV-1 RNA in successive plasma samples from eight seroconverting...

Human Immunodeficiency Virus Type 1 Subtype F Reverse Transcriptase Sequence and Drug Susceptibility

Apetrei, Cristian, Descamps, Diane, Collin, Gilles, Loussert-Ajaka, Ibtisam, Damond, Florence, Duca, Mihai, ...

We sequenced and phylogenetically analyzed the reverse transcriptase (RT) regions of the pol genes of 14 human immunodeficiency virus type 1 (HIV-1) isolates from Romanian patients, which were...

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

Hance, Allan J., Lemiale, Virginie, Izopet, Jacques, Lecossier, Denise, Joly, Véronique, Massip, Patrice, ...

Mutations in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and protease that confer resistance to antiretroviral agents are usually accompanied by a reduction in the viral...

Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir

Duval, Xavier, Lamotte, Claire, Race, Ester, Descamps, Diane, Damond, Florence, Clavel, François, ...

The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human...

Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial)

Joly, Véronique, Flandre, Philippe, Meiffredy, Vincent, Brun-Vezinet, Françoise, Gastaut, Jean-Albert, Goujard, Cécile, ...

We compared the efficacy and the toxicity of zidovudine (AZT) versus stavudine (d4T), in combination with lamivudine (3TC) and indinavir, in AZT-, dideoxyinosine (ddI)-, and/or dideoxycytosine...

Plasma RNA Viral Load in Human Immunodeficiency Virus Type 2 Subtype A and Subtype B Infections

Damond, Florence, Gueudin, Marie, Pueyo, Sophie, Farfara, Isabelle, Robertson, David L., Descamps, Diane, ...

Human immunodeficiency virus type 2 (HIV-2) is much less pathogenic than HIV-1, and HIV-2 infection is associated with plasma viral loads significantly lower than those found in HIV-1 infection. We...

R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen

Masquelier, Bernard, Droz, Cecile, Dary, Martin, Perronne, Christian, Ferré, Virginie, Spire, Bruno, ...

In 243 antiretroviral-naive human immunodeficiency-infected patients starting a first-line-protease inhibitor (mainly nelfinavir)-containing therapy, the presence of the polymorphism R57K in the...

Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs

Joly, Véronique, Descamps, Diane, Peytavin, Gilles, Touati, Fatiha, Mentre, France, Duval, Xavier, ...

We studied the evolution of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations among 29 human immunodeficiency virus type 1 (HIV-1)-infected patients who experienced virologic...

Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients

Marcelin, Anne-Geneviève, Cohen-Codar, Isabelle, King, Martin S., Colson, Philippe, Guillevic, Emmanuel, Descamps, Diane, ...

The genotypic inhibitory quotient (GIQ) has been proposed as a way to integrate drug exposure and genotypic resistance to protease inhibitors and can be useful to enhance the predictivity of...

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

Delaunay, Christophe, Brun-Vézinet, Françoise, Landman, Roland, Collin, Gilles, Peytavin, Gilles, Trylesinski, Aldo, ...

Tonus was a pilot study in which previously untreated human immunodeficiency virus type 1 (HIV-1)-infected patients received the combination of abacavir, lamivudine, and tenofovir once a day. There...

Improved Sensitivity of Human Immunodeficiency Virus Type 2 Subtype B Plasma Viral Load Assay

Damond, Florence, Collin, Gilles, Descamps, Diane, Matheron, Sophie, Pueyo, Sophie, Taieb, Audrey, ...

We developed a new assay for human immunodeficiency virus type 2 plasma RNA quantification based on a previous format. The new version performed significantly better than the original regarding the...

Quantification of Proviral Load of Human Immunodeficiency Virus Type 2 Subtypes A and B Using Real-Time PCR

Damond, Florence, Descamps, Diane, Farfara, Isabelle, Telles, Jean Noël, Puyeo, Sophie, Campa, Pauline, ...

We have developed and evaluated a new method to quantify human immunodeficiency virus type 2 (HIV-2) proviral DNA based on LightCycler real-time PCR. The assay has a detection limit of 5 copies/105...

Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors

Masquelier, Bernard, Race, Esther, Tamalet, Catherine, Descamps, Diane, Izopet, Jacques, Buffet-Janvresse, Claudine, ...

Genomic rearrangements in the 5′ part of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) have been involved in multidrug resistance to nucleoside RT inhibitors (NRTI). We...

Highly Sensitive Method for Amplification of Human Immunodeficiency Virus Type 2 DNA

Damond, Florence, Loussert-Ajaka, Ibtissam, Apetrei, Cristian, Descamps, Diane, Souquière, Sandrine, Leprêtre, Annie, ...

We evaluated a new human immunodeficiency virus type 2 (HIV-2) DNA amplification strategy based on peripheral blood mononuclear cell long PCR (XL PCR) followed by nested PCR amplification. The...

Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Mutations Conferring Resistance to Nucleoside Inhibitors of Reverse Transcriptase: Comparison with Sequence Analysis

Descamps, Diane, Calvez, Vincent, Collin, Gilles, Cécille, Agnès, Apetrei, Cristian, Damond, Florence, ...

We compared the line probe assay (LiPA) to sequence analysis for the detection of mutations conferring resistance to nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse...

Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants

Yerly, Sabine, Rakik, Abdelrahim, Kinloch De Loes, Sabine, Hirschel, Bernard, Descamps, Diane, Brun-Vézinet, Françoise, ...

Sequences of the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) domain were determined by direct sequencing of HIV-1 RNA in successive plasma samples from eight seroconverting...

Human Immunodeficiency Virus Type 1 Subtype F Reverse Transcriptase Sequence and Drug Susceptibility

Apetrei, Cristian, Descamps, Diane, Collin, Gilles, Loussert-Ajaka, Ibtisam, Damond, Florence, Duca, Mihai, ...

We sequenced and phylogenetically analyzed the reverse transcriptase (RT) regions of the pol genes of 14 human immunodeficiency virus type 1 (HIV-1) isolates from Romanian patients, which were...

Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy

Hance, Allan J., Lemiale, Virginie, Izopet, Jacques, Lecossier, Denise, Joly, Véronique, Massip, Patrice, ...

Mutations in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and protease that confer resistance to antiretroviral agents are usually accompanied by a reduction in the viral...

Amprenavir Inhibitory Quotient and Virological Response in Human Immunodeficiency Virus-Infected Patients on an Amprenavir-Containing Salvage Regimen without or with Ritonavir

Duval, Xavier, Lamotte, Claire, Race, Ester, Descamps, Diane, Damond, Florence, Clavel, François, ...

The efficacy of an amprenavir (APV)-containing therapy without (group A) or with (group B) ritonavir was assessed in patients with failure of previous protease inhibitor therapy for human...

Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial)

Joly, Véronique, Flandre, Philippe, Meiffredy, Vincent, Brun-Vezinet, Françoise, Gastaut, Jean-Albert, Goujard, Cécile, ...

We compared the efficacy and the toxicity of zidovudine (AZT) versus stavudine (d4T), in combination with lamivudine (3TC) and indinavir, in AZT-, dideoxyinosine (ddI)-, and/or dideoxycytosine...

Plasma RNA Viral Load in Human Immunodeficiency Virus Type 2 Subtype A and Subtype B Infections

Damond, Florence, Gueudin, Marie, Pueyo, Sophie, Farfara, Isabelle, Robertson, David L., Descamps, Diane, ...

Human immunodeficiency virus type 2 (HIV-2) is much less pathogenic than HIV-1, and HIV-2 infection is associated with plasma viral loads significantly lower than those found in HIV-1 infection. We...

R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen

Masquelier, Bernard, Droz, Cecile, Dary, Martin, Perronne, Christian, Ferré, Virginie, Spire, Bruno, ...

In 243 antiretroviral-naive human immunodeficiency-infected patients starting a first-line-protease inhibitor (mainly nelfinavir)-containing therapy, the presence of the polymorphism R57K in the...

Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs

Joly, Véronique, Descamps, Diane, Peytavin, Gilles, Touati, Fatiha, Mentre, France, Duval, Xavier, ...

We studied the evolution of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations among 29 human immunodeficiency virus type 1 (HIV-1)-infected patients who experienced virologic...

Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients

Marcelin, Anne-Geneviève, Cohen-Codar, Isabelle, King, Martin S., Colson, Philippe, Guillevic, Emmanuel, Descamps, Diane, ...

The genotypic inhibitory quotient (GIQ) has been proposed as a way to integrate drug exposure and genotypic resistance to protease inhibitors and can be useful to enhance the predictivity of...

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

Delaunay, Christophe, Brun-Vézinet, Françoise, Landman, Roland, Collin, Gilles, Peytavin, Gilles, Trylesinski, Aldo, ...

Tonus was a pilot study in which previously untreated human immunodeficiency virus type 1 (HIV-1)-infected patients received the combination of abacavir, lamivudine, and tenofovir once a day. There...

Improved Sensitivity of Human Immunodeficiency Virus Type 2 Subtype B Plasma Viral Load Assay

Damond, Florence, Collin, Gilles, Descamps, Diane, Matheron, Sophie, Pueyo, Sophie, Taieb, Audrey, ...

We developed a new assay for human immunodeficiency virus type 2 plasma RNA quantification based on a previous format. The new version performed significantly better than the original regarding the...

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors▿

Desbois, Delphine, Roquebert, Bénédicte, Peytavin, Gilles, Damond, Florence, Collin, Gilles, Bénard, Antoine, ...

We determine phenotypic susceptibility of human immunodeficiency virus type 2 (HIV-2) isolates to amprenavir, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, saquinavir, and tipranavir....

Tipranavir-Ritonavir Genotypic Resistance Score in Protease Inhibitor-Experienced Patients▿

Marcelin, Anne-Genevieve, Masquelier, Bernard, Descamps, Diane, Izopet, Jacques, Charpentier, Charlotte, Alloui, Chakib, ...

To identify mutations associated with the virological response (VR) to a tipranavir-ritonavir (TPV/r)-based regimen, 143 patients previously treated with protease inhibitor (PI) were studied. VR was...

Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss

Dam, Elisabeth, Quercia, Romina, Glass, Bärbel, Descamps, Diane, Launay, Odile, Duval, Xavier, ...

Human immunodeficiency virus type 1 (HIV-1) resistance to protease inhibitors (PI) results from mutations in the viral protease (PR) that reduce PI binding but also decrease viral replicative...

The Human Immunodeficiency Virus Type 2 Vpx Protein Usurps the CUL4A-DDB1DCAF1 Ubiquitin Ligase To Overcome a Postentry Block in Macrophage Infection▿ †

Bergamaschi, Anna, Ayinde, Diana, David, Annie, Le Rouzic, Erwann, Morel, Marina, Collin, Gilles, ...

The human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) genomes encode several auxiliary proteins that have increasingly shown their importance in the virus-host relationship....